These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31209157)

  • 1. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
    Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML; Passiglia F; Cappuzzo F; Minuti G; Occhipinti M; Bulotta A; Delmonte A; Sini C; Galetta D; Roca E; Pelizzari G; Cortinovis D; Gariazzo E; Pilotto S; Citarella F; Bria E; Muscolino P; Pozzessere D; Carta A; Pignataro D; Calvetti L; Leone F; Banini M; Di Micco C; Baldini E; Favaretto A; Malapelle U; Novello S; Pasello G; Tiseo M
    ESMO Open; 2024 Sep; 9(9):103680. PubMed ID: 39214048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
    Basse C; Régaldo-Saint Blancard L
    Bull Cancer; 2023 Sep; 110(9):869-871. PubMed ID: 37442707
    [No Abstract]   [Full Text] [Related]  

  • 10. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tepotinib in Non-Small-Cell Lung Cancer with
    Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
    N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
    Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
    Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
    Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
    Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
    Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
    Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
    Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW; Chang JW; Wu CE
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.